By Scientia Professor Gregory John Dore

Journal articles

Cheng Q; Valerio H; Cunningham EB; Shih STF; Silk D; Conway A; Treloar C; Murray C; Henderson C; Amin J; Read P; Dore GJ; Grebely J; Bath N; Milat A; Dunlop A; Holden J; Leadbeatter K; Day E; Habraken N; Dawson O; Degenhardt L; Scott C; Tillakeratne S; Marks P; Jayasinghe I; Martinez M; Reid H; Gleeson V; Van Dyk J; Mercade GE; Marshall AD; Obeid S; Wheeler A; Hooshyar SH; Catlett B; Verich A; Erratt A; Wheeler A; Ezard N; Reid D; Gorton C; Hayllar J; Lam T; Datta P; Wade A; Spruce S; Cock V; Cornwell M; Zohrab K; Christmass M; Connelly C; Cooper A; Montebello M; Cherry R; Dyer J; Arawal S; Press E; Horasak N; Lewis R; Carthew A; Morris D; Donohue K; Griffiths K; Lana JD; Shin S; Graf C; Hampson A; Qian S; Brown D; Lautier A; Curran C; Burns C; Raidu R; Stolzenhein K; Brabender W; Somes K; Abram N; Turne R; Larter S; Goodberg F; Luksza J; Hall M; Hazelwood S; Ismay C; McClurg B; Mincham C; Barlow K; Hoskins A; Salisbury K; Markham J; Talmet J; Dunn S; Mitchell A; McKinnon A; Smyth F; Snell L; Laing E; Clark M; Dorigo J, 2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225, http://dx.doi.org/10.1016/j.jval.2023.10.013

Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM, 2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofad637

Chaganti J; Poudel G; Cysique LA; Dore GJ; Kelleher A; Matthews G; Darley D; Byrne A; Jakabek D; Zhang X; Lewis M; Jha N; Brew BJ, 2024, 'Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesis', Frontiers in Neurology, 15, http://dx.doi.org/10.3389/fneur.2024.1350848

Bah R; Sheehan Y; Li X; Price N; Butler T; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B, 2024, 'Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2024.104401

Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ, 2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895

Grebely J; Matthews S; Causer LM; Feld JJ; Cunningham P; Dore GJ; Applegate TL, 2024, 'We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?', Expert Review of Molecular Diagnostics, 24, pp. 177 - 191, http://dx.doi.org/10.1080/14737159.2023.2292645

Shah SHBU; Valerio H; Hajarizadeh B; Matthews G; Alavi M; Dore GJ, 2023, 'Cascade of care among people with hepatitis B in New South Wales, Australia', Journal of Viral Hepatitis, 30, pp. 926 - 938, http://dx.doi.org/10.1111/jvh.13881

Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J, 2023, 'Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e1885 - e1898, http://dx.doi.org/10.1016/S2214-109X(23)00461-8

Hobday S; Valerio H; Combo T; Monaghan R; Scott C; Silk D; Murray C; Read P; Henderson C; Degenhardt L; Treloar C; Dore GJ; Grebely J; Martinello M, 2023, 'Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study', Drug and Alcohol Review, 42, pp. 1617 - 1632, http://dx.doi.org/10.1111/dar.13723

Cheng Q; Bajis S; Cunningham E; Shih STF; Schulz M; Marshall AD; Martin NK; Miners A; Hajarizadeh B; Wiseman V; Dore GJ; Grebely J, 2023, 'Health-related quality of life among people who inject drugs in Australia', Quality of Life Research, 32, pp. 3195 - 3207, http://dx.doi.org/10.1007/s11136-023-03465-3

Alter HJ; Barnes E; Biondi MJ; Cox AL; Eberts JD; Feld JJ; Liang TJ; Morrison J; Rice CM; Shoukry NH; Thomas DL; Van Gennip J; Weijer C; Aghemo A; Akiyama M; Ali M; Bader R; Bailey JR; Balaban Y; Banerjee S; Bartenschlager R; Baumert TF; Berenguer M; Bhadoria AS; Bonanni P; Bonella AE; Bruggmann P; Bruneau J; Bull RA; Butsashvili M; Cahn P; Caplan AL; Chappell RY; Chisari F; Chung R; Cooke G; Cox AL; Dalgard O; Dao DY; Darzi A; Dieterich D; Dillon JF; Dore GJ; Doyle JS; Drummer HE; Durbin AP; Dusheiko G; Eyal N; Ferguson K; Flisiak R; Forns X; Foster GR; Foung S; Gal-Tanamy M; Gane E; Gehring AJ; George J; Ghany MG; Gilbert DT; Glaze K; Goodman KW; Grebely J; Hamid S; Haybron DM; Holton R; Ignarro LJ; Jackson T; Jamieson D; Jollimore J; Karaba A; Klein M; Lauer G; Law M; Lemon SM; Liang TJ; Liu L; Lohmann V; Mak LY; Marinho RT; Marsh AA; Miller L; Negro F; Nguyen BV; Page K; Paterson K; Pedrana A; Pietschmann T; Pinker S; Plotkin S; Ray SC; Reau N; Remak WM; Ridruejo E; Roberts RJ, 2023, 'Joint statement in support of hepatitis C human challenge studies', The Lancet Gastroenterology and Hepatology, 8, pp. 967 - 969, http://dx.doi.org/10.1016/S2468-1253(23)00314-X

Martinello M; Bhagani S; Shaw D; Orkin C; Cooke G; Gane E; Iser D; Ustianowski A; Kulasegaram R; Stedman C; Tu E; Grebely J; Dore GJ; Nelson M; Matthews GV, 2023, 'Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study', JHEP Reports, 5, http://dx.doi.org/10.1016/j.jhepr.2023.100867

Razavi-Shearer DM; Gamkrelidze I; Pan CQ; Jia J; Berg T; Gray RT; Lim YS; Chen CJ; Ocama P; Desalegn H; Abbas Z; Abdallah AR; Aghemo A; Ahmadbekova S; Ahn SH; Aho I; Akarca US; Al Masri NM; Alalwan AM; Alavian SM; Al-Busafi SA; Aleman S; Alfaleh FZ; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Al-Rifai A; AlSerkal YM; Altraif IH; Amarsanaa J; Anderson M; Andersson MI; Armstrong P; Asselah T; Athanasakis K; Baatarkhuu O; Ben-Ari Z; Bensalem A; Bessone F; Biondi MJ; Bizri ARN; Blach S; Braga WSM; Brandão-Mello CE; Brosgart CL; Brown KA; Brown RS; Bruggmann P; Brunetto MR; Buti M; Cabezas J; Casanovas T; Chae C; Chan HLY; Cheinquer H; Chen PJ; Cheng KJG; Cheon ME; Chien CH; Choudhuri G; Christensen PB; Chuang WL; Chulanov V; Cisneros Garza LE; Coffin CS; Contreras FA; Coppola N; Cornberg M; Cowie B; Cramp ME; Craxi A; Crespo J; Cui F; Cunningham CW; Dalgard O; De Knegt RJ; De Ledinghen V; Dore GJ; Drazilova S; Duberg AS; Egeonu S; Elbadri M; El-Kassas M; El-Sayed MH; Estes C; Etzion O; Farag E; Ferradini L; Ferreira PRA; Flisiak R; Forns X; Frankova S; Fung J; Gane EJ; Garcia V; Garcia-Samaniego J; Gemilyan M; Genov J; Gheorghe LS, 2023, 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study', The Lancet Gastroenterology and Hepatology, 8, pp. 879 - 907, http://dx.doi.org/10.1016/S2468-1253(23)00197-8

Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV, 2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651

Martinello M; Solomon SS; Terrault NA; Dore GJ, 2023, 'Hepatitis C', The Lancet, 402, pp. 1085 - 1096, http://dx.doi.org/10.1016/S0140-6736(23)01320-X

Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J, 2023, 'A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study', Journal of Hepatology, 79, pp. 635 - 644, http://dx.doi.org/10.1016/j.jhep.2023.04.019

Carson JM; Barbieri S; Cunningham E; Mao E; van der Valk M; Rockstroh JK; Hellard M; Kim A; Bhagani S; Feld JJ; Gane E; Thurnheer MC; Bruneau J; Tu E; Dore GJ; Matthews GV; Martinello M, 2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168, http://dx.doi.org/10.1002/jia2.26168

Feld JJ; Bruneau J; Dore GJ; Ghany MG; Hansen B; Sulkowski M; Thomas DL, 2023, 'Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations', Clinical Infectious Diseases, 77, pp. S262 - S269, http://dx.doi.org/10.1093/cid/ciad362

Koopsen J; Matthews G; Rockstroh J; Applegate TL; Bhagani S; Rauch A; Grebely J; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard M; Dore GJ; Schinkel J; van der Valk M; Adams T; Amjad S; Appelhans C; Becker B; Bouchard R; Braun D; Bruelisauer C; Calcagnile S; Carroll A; Cerocchi O; Chronister K; Cordes C; Dore G; Evans F; Fedele S; Ferguson C; Fraser C; Ganase B; Gane E; George V; Gerlach C; Gilleece Y; Gilliver R; Grube C; Gustafson J; Haas A; Hagenauer M; Harris M; Helder J; Hirter D; Hull M; Katz S; Kim A; Kotsoros B; Lacalamita M; Lindergard G; Lutz T; Macabodbod L; Manz M; Marks P; Messina P; Mohrmann K; Monnich C; Moon J; Moriggia A; Morris G; Morrish T; Nelson M; Oliver V; Patterson J; Peters M; Petoumenos K; Porretta H; Raymode P; Read P; Reece S; Saidi A; Sasadeusz J; Scherler P; Schröder R; Selfridge M; Sevehon A; Shaw D; Sulkowski M; Tamaddoni M; Thunder O; Thurnheer MC; Tu E; Ustianowski A; Witele E, 2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', The Lancet Microbe, 4, pp. e622 - e631, http://dx.doi.org/10.1016/S2666-5247(23)00108-8

Cysique LA; Jakabek D; Bracken SG; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Staats Pires A; Darley DR; Byrne A; Phetsouphanh C; Kelleher A; Dore GJ; Matthews GV; Guillemin GJ; Brew BJ, 2023, 'The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC', Annals of Clinical and Translational Neurology, 10, pp. 1338 - 1352, http://dx.doi.org/10.1002/acn3.51825

Price O; Maher L; Dietze PM; Bruno R; Crawford S; Sutherland R; Salom C; Dore GJ; Peacock A, 2023, 'COVID-19 vaccine attitudes and facilitators among people in Australia who inject drugs', Drug and Alcohol Review, 42, pp. 1066 - 1077, http://dx.doi.org/10.1111/dar.13621

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon JA; Lloyd AR; Dore GJ; Wiseman V; Grebely J, 2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', The Lancet Regional Health - Western Pacific, 36, http://dx.doi.org/10.1016/j.lanwpc.2023.100750

Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Valerio H; Dore GJ, 2023, 'Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets', Journal of Viral Hepatitis, 30, pp. 520 - 529, http://dx.doi.org/10.1111/jvh.13824

Cheng Q; Cunningham EB; Shih S; Amin J; Bruneau J; Artenie AA; Powis J; Litwin AH; Cooper C; Dalgard O; Hellard M; Bruggmann P; Marks P; Lacombe K; Stedman C; Read P; Hajarizadeh B; Dunlop AJ; Conway B; Feld JJ; Dore GJ; Grebely J; Dore G; Crawford S; Swan T; Byrne J; Coordinating Centre—Amanda Erratt ML; Marks P; Shaw I; Siriragavan S; Quiene S; Petoumenos K; Schmid P; Castro E; Moriggia A; Daulouede JP; Fraser C; Feld J; Gane E; Matthews G; Kronborg I; Shaw D; Norton B; Thurnheer MC; Weltman M; Dillon J; Kessler S; Knapp C; Oprandi L; Messina P; Pantic M; Le Cam M; Maitre C; Andreassen J; Melkeraaen I; Tollefsen MM; Pagarigan H; Milne R; Mason K; Kaznowski D; Zou L; Bouchard R; Kotsoros B; Muir M; Milloy J; Oliver V; Noonan T; Sevehon A; Hazelwood S; Hall M; Hagenauer M; Liddle R; Ferguson C; Agyemang L; Patel H; Soloway I; Cerocchi O; Lacalamita M; Fragomeli V; Gilliver R; Lothian R; Cleary S; Johnston L; Middleton S; D'Amico R; McGovern B; Anderson J; Zhong Z; Keane F; Tatsch F; Brainard D; McHutchison J, 2023, 'Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs', Value in Health, 26, pp. 883 - 892, http://dx.doi.org/10.1016/j.jval.2022.12.016

Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270) (Journal of Hepatology (2023) 78(2) (260–270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084, http://dx.doi.org/10.1016/j.jhep.2023.02.020

Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J, 2023, 'Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e659 - e672, http://dx.doi.org/10.1016/S2214-109X(23)00057-8

Colledge-Frisby S; Ottaviano S; Webb P; Grebely J; Wheeler A; Cunningham EB; Hajarizadeh B; Leung J; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Degenhardt L, 2023, 'Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e673 - e683, http://dx.doi.org/10.1016/S2214-109X(23)00058-X

Iversen J; Wand H; McManus H; Dore GJ; Maher L, 2023, 'Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies', Addiction, 118, pp. 901 - 911, http://dx.doi.org/10.1111/add.16113

Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Hayllar J; Grebely J; Marshall AD, 2023, '“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103998

Carson J; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125, http://dx.doi.org/10.1097/HC9.0000000000000125

Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P, 2023, 'Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103982

Grebely J; Markus C; Causer LM; Silk D; Comben S; Lloyd AR; Martinez M; Cunningham EB; O'Flynn M; Dore GJ; Matthews S, 2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', The Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207, http://dx.doi.org/10.1016/S2468-1253(22)00355-7

Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261, http://dx.doi.org/10.1111/jvh.13791

Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P, 2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469

Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270, http://dx.doi.org/10.1016/j.jhep.2022.09.011

Schiavone B; Dore GJ; Stone E; Matthews GV; Darley DR, 2023, 'An update on long COVID and its management', Medicine Today, 24, pp. 37 - 43

Jessica HB; Carson J; Scott M; Patricia C; Nelson R; Helen VG; Phillip R; Hanson J; Robert M; Matthews G; Dore GJ; Martinello M; Read P, 2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803

Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ, 2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761

Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2022.103917

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2015.11.011

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669, http://dx.doi.org/10.1016/j.drugpo.2015.11.009

Morpeth SC; Venkatesh B; Totterdell JA; McPhee GM; Mahar RK; Jones M; Bandara M; Barina LA; Basnet BK; Bowen AC; Burke AJ; Cochrane B; Denholm JT; Dhungana A; Dore GJ; Dotel R; Duffy E; Dummer J; Foo H; Gilbey TL; Hammond NE; Hudson BJ; Jha V; Jevaji PR; John O; Joshi R; Kang G; Kaur B; Kim S; Das SK; Lau JSY; Littleford R; Marsh JA; Marschner IC; Matthews G; Maze MJ; McArthur CJ; McFadyen JD; McMahon JH; McQuilten ZK; Molton J; Mora JM; Mudaliar V; Nguyen V; O'Sullivan MVN; Pant S; Park JE; Paterson DL; Price DJ; Raymond N; Rees MA; Robinson JO; Rogers BA; Ryu W-S; Sasadeusz J; Shum O; Snelling TL; Sommerville C; Trask N; Lewin SR; Hills TE; Davis JS; Roberts JA; Tong SYC, 2023, 'A Randomized Trial of Nafamostat for Covid-19.', NEJM Evid, 2, pp. EVIDoa2300132, http://dx.doi.org/10.1056/EVIDoa2300132

Shah SHBU; Valerio H; Hajarizadeh B; Alavi M; Matthews G; Dore G, 2023, 'Cascade of care among people with an HBV notification in New SouthWales, Australia, including diagnosis, specialist assessment, and treatment uptake', JOURNAL OF HEPATOLOGY, 78, pp. S910 - S910

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, 2022, 'High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1032911

Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J, 2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876

Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246

Lazarus JV; Romero D; Kopka CJ; Karim SA; Abu-Raddad LJ; Almeida G; Baptista-Leite R; Barocas JA; Barreto ML; Bar-Yam Y; Bassat Q; Batista C; Bazilian M; Chiou ST; del Rio C; Dore GJ; Gao GF; Gostin LO; Hellard M; Jimenez JL; Kang G; Lee N; Matičič M; McKee M; Nsanzimana S; Oliu-Barton M; Pradelski B; Pyzik O; Rabin K; Raina S; Rashid SF; Rathe M; Saenz R; Singh S; Trock-Hempler M; Villapol S; Yap P; Binagwaho A; Kamarulzaman A; El-Mohandes A; Barreto M; Abdulla S; Addleman S; Aghayeva G; Agius R; Ahmed M; Ramy MA; Aide P; Aleman S; Alfred JP; Ali S; Aliaga J; Aloudat T; Alqahtani SA; Al-Salman J; Amuasi JH; Agrawal A; Anwar W; Araujo-Jorge T; Artaza O; Asadi L; Awuku Y; Baker M; Barberia L; Bascolo E; Belcher P; Bell L; Benzaken A; Bergholtz E; Bhadelia N; Bhan A; Bilodeau S; Bitrán R; Bluyssen P; Bosman A; Bozza FA; Brinkmann MM; Brown A; Mellado B; Bukusi E; Bullen C; Buonanno G; Burgess R; Butler M; Byakika-Kibwika P; Cabieses B; Carlsson G; Cascini F; Chabala C; Chakroun M; Cheng KK; Chetty A; Chumachenko D; Consalves G; Conway Morris A; Cordie A; Corrah T; Crabtree-Ramírez B; Dashdorj N; Davidovitch N, 2022, 'A multinational Delphi consensus to end the COVID-19 public health threat', Nature, 611, pp. 332 - 345, http://dx.doi.org/10.1038/s41586-022-05398-2

Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J, 2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14, http://dx.doi.org/10.3390/v14112463

Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Kaldor J; Dore G; Sorrell T; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Sultan R; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272

Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA, 2022, 'Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review', Clinical Pharmacokinetics, 61, pp. 1331 - 1343, http://dx.doi.org/10.1007/s40262-022-01170-x

Back to profile page